SertralineThird Party Manufacturing in India

Sertraline is a selective serotonin reuptake inhibitor that potentiates serotonergic activity in the central nervous system by blocking the reuptake of serotonin at the presynaptic neuronal membrane, thereby increasing the availability of this neurotransmitter in the synaptic cleft.

Sertraline binds with high affinity to the serotonin transporter (SERT) on presynaptic nerve terminals. By occupying the transporter binding site, sertraline prevents the reabsorption of serotonin back into the presynaptic neuron following its release into the synapse. This inhibition of serotonin reuptake leads to an accumulation of serotonin in the synaptic space, allowing sustained activation of both postsynaptic and presynaptic serotonin receptors (including 5-HT₁A, 5-HT₁B, 5-HT₂A, and 5-HT₃ subtypes). The enhanced serotonergic neurotransmission gradually normalises mood, anxiety, and compulsive behaviour patterns over several weeks of continuous therapy.

Unlike tricyclic antidepressants, sertraline exhibits minimal affinity for adrenergic, cholinergic, histaminergic, GABAergic, and dopaminergic receptors, which results in a more favourable side effect profile with less sedation, dry mouth, and constipation. Sertraline also has weak inhibitory effects on dopamine reuptake, which may contribute to its unique efficacy profile and lower risk of cognitive impairment compared to other SSRIs. Its relatively long half-life of approximately 26 hours allows for once-daily dosing, improving patient compliance in long-term maintenance therapy for chronic psychiatric conditions.

Therapeutic Uses

Sertraline is prescribed for the treatment of:

• Major Depressive Disorder (MDD): First-line pharmacotherapy for moderate to severe depression. Sertraline improves mood, sleep quality, appetite, energy levels, and restores interest in daily activities. Clinical response typically begins within two to four weeks, with full therapeutic benefit achieved by eight to twelve weeks.
• Obsessive-Compulsive Disorder (OCD): Approved for both adult and paediatric patients (ages 6 and above). Sertraline significantly reduces the frequency and intensity of obsessions and compulsions, making it the most prescribed SSRI for OCD worldwide.
• Panic Disorder: Reduces the frequency and severity of panic attacks, including those with or without agoraphobia. Low starting doses are required to avoid initial anxiety exacerbation.
• Post-Traumatic Stress Disorder (PTSD): Effective in reducing intrusive thoughts, hypervigilance, avoidance behaviours, and emotional numbing associated with trauma exposure.
• Social Anxiety Disorder (Social Phobia): Improves functioning in social and performance situations by reducing anticipatory anxiety and fear of negative evaluation.
• Premenstrual Dysphoric Disorder (PMDD): Administered either continuously or intermittently during the luteal phase for relief of mood swings, irritability, and physical symptoms.

Why Manufacturers Choose Sertraline

Sertraline is one of the World Health Organization's Essential Medicines and holds the largest market share among SSRIs globally. Its extensive patent expiry has created a thriving generic market, with India being the largest manufacturer and exporter of sertraline tablets worldwide. The drug is available in three well-established tablet strengths — 25mg, 50mg, and 100mg — all of which use the same granulation and compression process, making production scale-up straightforward. Indian manufacturers supply sertraline to regulated markets including the United States (USP standards), Europe (EP standards), and the UK (BP standards), requiring a dual or triple pharmacopoeia compliance capability. The API is abundantly available from multiple domestic manufacturers, ensuring stable raw material pricing.

This makes Sertraline one of the most reliable molecules for third party manufacturing in India, with consistent institutional and retail demand across both domestic and export channels.